Q32 Bio And Homology Medicines Have Agreed To Combine In An All-stock Transaction. The Combined Company Will Focus On Advancing Q32 Bio's Candidates For Autoimmune And Inflammatory Diseases
. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol "QTTB".